Identification and Validation of Mannose Metabolism-Related Biomarkers in COPD Through Integrated Bioinformatics and Machine Learning Analysis: A Pilot Study. [PDF]
Li X, Wang J, Hu Z, Chen S, Liu C.
europepmc +1 more source
Aberrant glycosylation in schizophrenia: insights into pathophysiological mechanisms and therapeutic potentials. [PDF]
Feng Y +10 more
europepmc +1 more source
Stress-induced secretory pathway disruption causes atypical metalloproteinase transport in PMM2-CDG. [PDF]
Wu CL +6 more
europepmc +1 more source
Defining albumin as a glycoprotein with multiple N-linked glycosylation sites. [PDF]
Garapati K +6 more
europepmc +1 more source
In vivo base editing reduces liver cysts in autosomal dominant polycystic kidney disease. [PDF]
Ibel A +17 more
europepmc +1 more source
Systemic gene therapy corrects the neurological phenotype in a mouse model of NGLY1 deficiency. [PDF]
Du A +9 more
europepmc +1 more source
Aspartylglycosamine Is a Biomarker for NGLY1-CDDG, a Congenital Disorder of Deglycosylation
NGLY1-CDDG is a congenital disorder of deglycosylation caused by a defective peptide:N-glycanase (PNG). To date, all but one of the reported patients have been diagnosed through whole-exome or whole-genome sequencing, as no biochemical marker was available to identify this disease in patients.
Berthil Prinsen +2 more
exaly +6 more sources
Related searches:
Acute Liver Failure in a Male Patient With NGLY1-Congenital Disorder of Deglycosylation
European Journal of Medical Genetics, 2020Congenital disorder of N-linked deglycosylation (CDDG, MIM 615273) is a very rare autosomal recessive disorder caused by pathogenic variants in the NGLY1 gene. Transient transaminitis is the typical hepatic dysfunction described in these patients, but also included neonatal jaundice, hepatomegaly, splenomegaly, and steatosis.
Lucina Bobadilla-Morales +2 more
exaly +3 more sources

